Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase I/II Study of Durvalumab and Stereotactive Ablative Body Radiotherapy in Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

Summary

The purpose of this phase I/II study is to determine the safety and tolerability of durvalumab in combination with stereotactive ablative radiotherapy (SABR), a standard radiation treatment, for patients with pancreatic cancer.

General Information

NCT#: NCT03245541
Study ID: IIT2016_01_Tuli_DURVARAD
Trial Phase: Phase I/II

Trial Sponsor: AstraZeneca, Cedars-Sinai Medical Center
Therapies Used in This Trial: Durvalumab, Stereotactic Ablative Radiotherapy (SABR)

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search